Anteris Technologies Ltd (ASX:AVR) has achieved a breakthrough in manufacturing the tissue used in ADAPT® treated products from bovine pericardium, after developing specialised machinery to create consistently thin tissue through an innovative processing technique.
This process reduces the native pericardia thickness to yield tissue with the desired thickness to make its 3D single-piece aortic valves.
Valve durability studies
Anteris says thinning tissue on-demand is a challenging engineering feat, which is achieved by several custom equipment iterations and parameter adjustments.
Tissue tests demonstrated tensile strength properties equivalent to current ADAPT® treated pericardia.
Valve durability studies proving absolute equivalence between the processed tissue and native (thin) tissue are the confirmatory next step.
Importantly, Anteris has lodged patent applications to protect its intellectual property in this breakthrough development.
Key takeaways
- Prior to AVR’s success, the ability to thin tissue was not achievable;
- This accomplishment took several years with a specialised machine the company built from the ground up; and
- This technique once proven up at commercial scale has the ability to increase yields and decrease manufacturing costs.
Selected to showcase transcatheter heart valve
The company’s transcatheter heart valve has been handpicked for a presentation at the Transcatheter Valve Therapies (TVT) Structural Heart Summit next month.
The ASX-lister will facilitate a presentation at the summit’s ‘The Call For Innovation’ segment, focused on its 3D single-piece DurAVR™ THV heart valve.
During the presentation, the company intends to expand on the heart valve’s innovative qualities, the benefits it brings to patients and ways it “lasts longer and works better” than devices currently available.